Acasti Pharma (id:6030 ACST)
3.28 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 3:37:22 PM)
Exchange closed, opens in 1 day 17 hours
3.14 USD (3.14%)
5.81 USD (5.81%)
-0.30 USD (-0.30%)
21.48 USD (21.48%)
56.19 USD (56.19%)
-96.68 USD (-96.68%)
-98.45 USD (-98.45%)
-99.37 USD (-99.37%)
About Acasti Pharma
Market Capitalization 34.17M
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
| Headquarters (address) |
103 Carnegie Center Princeton 08540 NJ United States |
| Phone | 818-839-4378 |
| Website | https://www.acastipharma.com |
| Employees | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ACST |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.98 - 3.60 |
| Market Capitalization | 34.17M |
| P/E trailing | -1.87 |
| P/E forward | -2.67 |
| Price/Book | 0.576 |
| Beta | 1.52 |
| EPS | -1.43 |
| EPS United States (ID:6, base:3402) | 24.25 |